FDA.reportPublic FDA data

PHESGO 1,200 MG / 600 MG / 30,000 UNT in 15 ML Injection

RxCUI
2382609
RxNorm name
PHESGO 1,200 MG / 600 MG / 30,000 UNT in 15 ML Injection
Display name
PHESGO 1,200 MG / 600 MG / 30,000 UNT in 15 ML Injection
Full name
PHESGO 1,200 MG / 600 MG / 30,000 UNT in 15 ML Injection
Term type
PSN
Status
DailyMed mapping
Updated
2026-06-04 23:38:51

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761170Phesgopertuzumab, trastuzumab, and hyaluronidase-zzxf351(a)Rx2026-07-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
PhesgoPERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXFGenentech, Inc.27dd5e6b-72cd-458d-a015-cf4dab5800da2026-05-21Boxed warning, Warnings, Adverse reactionsExact identifier
rxcui: 2382609

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
27dd5e6b-72cd-458d-a015-cf4dab5800daPHESGO 1,200 MG / 600 MG / 30,000 UNT in 15 ML Injection [PSN] · 15 ML hyaluronidase-zzxf 2000 UNT/ML / pertuzumab-zzxf 80 MG/ML / trastuzumab-zzxf 40 MG/ML Injection [Phesgo] [SBD] · Phesgo 1,200 MG / 600 MG / 30,000 UNT per 15 ML Injection [SY]317These highlights do not include all the information needed to use PHESGO safely and effectively. See full prescribing information for PHESGO. PHESGO ® (pertuzumab, trastuzumab, and hyaluronidase-zzxf) injection, for subcutaneous use Initial U.S. Approval: 202020260521